Alnylam Pharmaceuticals
Medical Science Liaison (Finance)
Medical Science Liaison
Overview
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases with unmet need. Our first medicine, the first-ever RNAi therapeutic, has recently been approved by the FDA in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. In addition, Alnylam has four investigational medicines in late-stage development. www.alnylam.com . Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work in 2015, 2016, 2017 and 2018-- four years in a row!
The Medical Science Liaison is a field-based scientific and clinical expert that strategically supports the medical and scientific objectives of Alnylam's investigational programs.
He/she will be accountable to communicate the science and clinical application of RNAi to Healthcare Practitioners (HCPs). In addition, MSLs are expected to build strong cross-functional relationships with colleagues in Medical Affairs, Clinical Research, R&D, Patient Advocacy and Commercial Operations, while maintaining full compliance with all relevant company, industry, legal, and regulatory requirements.
Summary of Key Responsibilities
Qualifications
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment.